Search PubMed⌕ Search

Biomedical subjects

F Smith

Publications and source records attributed to F Smith.

209 records · Page 12Linked to original sources
PubMedDate not supplied

Reduced cardiac selenium content in the acquired immunodeficiency syndrome.

Selenium deficiency has been implicated in the pathogenesis of a dilated congestive cardiomyopathy in areas of China (Keshan disease) and in several patients on long-term total parenteral nutrition. Recently a clinically and pathologically similar cardiomyopathy has been described in AIDS. Since blood selenium levels are low in AIDS, we assayed cardiac selenium status by a spectrofluorometric method in eight AIDS patients at autopsy compared to nine age-matched, non-AIDS autopsy controls with histologically normal hearts. We found (mean +/- SD) a cardiac selenium level of 0.327 +/- 0.082 microgram/g dry weight in AIDS vs 0.534 +/- 0.184 microgram/g dry weight in controls (p less than 0.01; Student's t test). There were no significant differences between the groups for heart weight, serum CPK, or other laboratory parameters. No specific chest x-ray or electrocardiographic abnormalities were present. Histologically, all AIDS hearts were abnormal; mostly with mild degrees of muscle hypertrophy or fibrosis. Foci of myocytolysis and myocyte necrosis and fibrous replacement of myocytes and monocytic infiltration were present in two AIDS cases. We conclude that heart tissue in AIDS demonstrates a significant selenium deficit. These data provide a potential link between selenium deficiency and cardiomyopathy in AIDS.

Acquired Immunodeficiency Syndrome↗
PubMedDate not supplied

Are employees satisfied? A survey of occupational health services.

With stepped-up efforts to contain costs, there is widespread concern that medical facilities and insurance carriers are not paying enough attention to accident prevention. This recent study of occupational health services reveals that patients supported by private insurance appear to be less than satisfied with the quality of care when they are treated for work-related injuries or illnesses in industrial clinics. However, when a health or safety consultant is on staff, patient attitudes improve markedly. There is clearly an increasing role for health educators in facilitating a better understanding among patients of industrial medical resources.

Accidents, Occupational↗
PubMedDate not supplied

Vocabulary training.

Explore the source record for details and available documents.

Education of Persons with Intellectual Disabilitie↗
PubMedDate not supplied

Phase I clinical trial of spirogermanium.

Spirogermanium is a new azaspirane antitumor agent, with the metal germanium substituted for a one-carbon moiety in the ring structure. This drug inhibits DNA and RNA synthesis in HeLa cells, is cytotoxic in vitro, and has curative in vivo antitumor activity against the ascitic Walker 256 carcinosarcoma in rats. No hematologic toxicity was recorded during the preclinical toxicologic evaluation. The principal clinical toxic effects observed in this phase I trial were neurologic, manifested as lethargy, dizziness, and ataxia, while a grand mal seizure was produced after an accidental overdose. There was no evidence of hematologic, renal, or hepatic toxicity. A partial response was achieved in a patient with a well-differentiated lymphocytic lymphoma. We recommend that phase II trials be conducted with a twice or thrice weekly dose of 50-80 mg/m2, administered in a 30-minute iv infusion.

Adult↗
PubMedDate not supplied

Guanazole (NSC-1895)--a phase I clinical study.

Two dose schedules of guanazole were used in this phase I clinical study: intermittent prolonged 5-day infusion and intermittent iv bolus twice weekly. Ninety-seven treatment observations were analyzed for toxic effects resulting from the prolonged infusion and 42 from the twice-weekly bolus schedule. The main toxic effect was bone marrow suppressions, the frequency and severity of which were intensified by prior chemotherapy or radiotherapy and repetition of guanazole therapy. The leukocyte count was affected more than the platelet count. Partial responses were observed in four patients: two with lung carcinoma, one with prostate carcinoma, and one with melanoma. Further phase II clinical studies of guanazole are indicated.

Clinical Trials as Topic↗